Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Fulcrum Therapeutics, Inc. (FULC)

Fulcrum agrees to all-stock merger with Slate Medicines, a migraine drug developer

Mixed Impact 5 of 5 m&a Written later

Fulcrum Therapeutics signed a merger agreement on August 16, 2026, under which Slate Medicines will combine with Fulcrum in an all-stock deal, with the combined company to be renamed Slate Medicines. Fulcrum expects to pay its pre-merger stockholders a cash dividend of $270 million, but those holders are expected to own only about 5.0% of the combined company, subject to adjustment based on Fulcrum's net cash at closing.

Key points

  • Pre-merger Fulcrum stockholders are expected to own about 5.0% of the combined company on a fully diluted basis.
  • Fulcrum expects to declare a cash dividend of $270 million to its pre-merger stockholders in connection with the closing.
  • A concurrent private placement of approximately $245.0 million is a closing condition, and the closing is expected in the fourth quarter of 2026.
  • Termination fees are $10 million payable by Fulcrum and $15 million payable by Slate in certain circumstances.

The filing

CompanyFulcrum Therapeutics, Inc. (FULC)
Form8-K, current report
Filed with the SECAug 17, 2026, 8:30 AM ET
Accession number0001193125-26-353278

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale5.01 Change in Control5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 17, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.